Last updated: February 19, 2026
MYRBETRIQ GRANULES (mirabegron extended-release) is a beta-3 adrenergic agonist approved for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urge urinary frequency. The drug's market performance is shaped by its therapeutic profile, patent landscape, and competitive environment.
What is the Current Market Position of MYRBETRIQ GRANULES?
MYRBETRIQ GRANULES competes in the OAB market, a segment characterized by a significant patient population and ongoing development of therapeutic options. The drug was developed by Astellas Pharma and has been a key product in its urology portfolio.
- Approved Indications: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urge urinary frequency.
- Mechanism of Action: MYRBETRIQ stimulates beta-3 adrenergic receptors in the bladder detrusor muscle, leading to relaxation and increased bladder capacity. This differs from anticholinergic OAB treatments, which work by blocking acetylcholine.
- Market Share: While specific current market share data fluctuates, MYRBETRIQ has historically held a significant position among prescription OAB treatments. Its market penetration is influenced by physician prescribing habits and patient access.
- Competitive Landscape: The OAB market includes other branded and generic medications. Key competitors include anticholinergic agents (e.g., tolterodine, oxybutynin, solifenacin) and newer OAB therapies. The availability of generic alternatives for some older anticholinergics creates a pricing dynamic that MYRBETRIQ must navigate.
What is the Patent Status and Exclusivity Landscape for MYRBETRIQ GRANULES?
The patent exclusivity for MYRBETRIQ GRANULES is a critical factor influencing its market trajectory and revenue potential. Astellas Pharma has secured patents covering the composition of matter, formulation, and methods of use for mirabegron.
- Composition of Matter Patent: The foundational patent for mirabegron itself is a key asset. Expiration of this patent typically opens the door for generic manufacturers.
- Formulation Patents: Patents covering the extended-release formulation of MYRBETRIQ are also significant, as they can provide additional layers of exclusivity beyond the active ingredient patent. These patents can protect the specific delivery system that enhances patient convenience and therapeutic efficacy.
- Key Exclusivity Dates:
- US Patent Expiration: Several key patents protecting MYRBETRIQ have expired or are nearing expiration. For instance, U.S. Patent No. 8,603,514, related to methods of treating OAB, has an expiration date in the near future. Other patents covering the drug substance and formulations also exist.
- Orphan Drug Exclusivity (ODE): MYRBETRIQ did not receive Orphan Drug Exclusivity, as OAB is not considered a rare disease.
- Pediatric Exclusivity: Astellas Pharma received a six-month pediatric exclusivity extension in the U.S., pushing the market exclusivity of MYRBETRIQ until September 2017. This was a standard extension granted for conducting studies in pediatric populations.
- Generic Entry: With the expiration of key patents, the market has seen the introduction of generic mirabegron products. The timing and impact of generic entry significantly affect the pricing power and market share of the branded product.
What is the Financial Performance and Revenue Trajectory of MYRBETRIQ GRANULES?
MYRBETRIQ GRANULES has been a significant revenue generator for Astellas Pharma. Its financial trajectory is a direct reflection of its market penetration, pricing strategy, and the impact of patent expirations.
- Peak Sales: MYRBETRIQ reached peak annual sales in the range of $1.5 billion to $1.7 billion globally. This peak was achieved prior to significant generic competition.
- Revenue Trends:
- Growth Phase: In its initial years post-launch (launched in the U.S. in 2012), MYRBETRIQ experienced strong sales growth as it gained physician adoption and established its efficacy and safety profile.
- Maturity and Decline: Following patent expirations and the subsequent introduction of generic mirabegron, the revenue trajectory for branded MYRBETRIQ has entered a decline. This is a standard pattern for branded pharmaceuticals once generic competition emerges.
- Sales Breakdown: Global sales are typically reported by Astellas Pharma, with North America historically being the largest market. Japan and Europe also represent significant, though smaller, markets.
- Impact of Generics: The introduction of generic mirabegron in key markets has led to significant price erosion for the branded product. This price pressure reduces the overall revenue generated by MYRBETRIQ, even if unit sales for mirabegron as a molecule remain substantial across branded and generic forms.
- Astellas Pharma's Financial Reporting: Astellas Pharma's financial reports provide quarterly and annual sales figures for MYRBETRIQ. These reports serve as the primary source for tracking its revenue performance. For example, in their fiscal year 2022 reports, sales figures indicated a downward trend for the branded product due to generic competition.
How Does the Competitive Landscape Affect MYRBETRIQ GRANULES?
The competitive dynamics within the OAB market directly influence the prescription volume and pricing power of MYRBETRIQ GRANULES.
- Anticholinergic Dominance: For many years, anticholinergic agents have been the first-line therapy for OAB due to their long history of use and established efficacy. MYRBETRIQ, as a non-anticholinergic option, provided an alternative for patients who did not tolerate or respond to anticholinergics.
- Generic Anticholinergics: The availability of inexpensive generic versions of older anticholinergic drugs presents a significant cost-based challenge. These generics often have lower price points, making them an attractive option for payers and a cost-effective choice for patients and healthcare systems.
- Emerging Therapies: The OAB market continues to evolve with new therapeutic approaches, including other beta-3 agonists, novel drug delivery systems, and non-pharmacological interventions. While MYRBETRIQ was an innovation, ongoing research and development by competitors necessitate continuous evaluation of its competitive standing.
- Comparative Efficacy and Safety: Physicians weigh the comparative efficacy, safety profiles, and side effect profiles of different OAB treatments when making prescribing decisions. MYRBETRIQ's distinct mechanism of action offers a benefit for patients experiencing side effects like dry mouth, constipation, and cognitive issues associated with anticholinergics.
- Payer Influence: Pharmacy benefit managers (PBMs) and insurance companies play a crucial role in market access. Formulary placement, prior authorization requirements, and co-payment structures can significantly influence which OAB medications are prescribed. The cost-effectiveness of MYRBETRIQ relative to generics and other branded options is a key consideration for payers.
What are the Key Challenges and Opportunities for MYRBETRIQ GRANULES?
MYRBETRIQ GRANULES faces a dynamic market environment with both significant challenges and persistent opportunities.
Challenges
- Generic Erosion: The primary challenge is the ongoing erosion of market share and pricing power due to the introduction of generic mirabegron. This trend is irreversible for the branded product.
- Cost-Effectiveness Pressure: Healthcare systems and payers exert increasing pressure to demonstrate cost-effectiveness. Branded drugs with generic alternatives face scrutiny regarding their value proposition.
- Physician Inertia: While MYRBETRIQ offers an alternative mechanism, some physicians may continue to favor established anticholinergic regimens due to familiarity or cost considerations for their patients.
- Market Saturation: The OAB market is well-established with numerous treatment options, leading to a highly competitive environment.
Opportunities
- Continued Patient Need: OAB remains a prevalent condition affecting millions of individuals, ensuring a sustained patient population seeking effective treatment.
- Non-Anticholinergic Alternative: MYRBETRIQ's mechanism of action continues to be a differentiating factor for patients who cannot tolerate or are contraindicated for anticholinergic therapy. This niche remains important.
- Combination Therapies: Research and development into OAB treatments may explore combination therapies that could involve mirabegron or its derivatives, though this is more speculative for the existing branded product.
- Geographic Expansion (though limited by generics): While major markets are impacted by generics, there may be residual opportunities in markets with later patent expiries or different regulatory timelines, although this is diminishing.
- Life Cycle Management (historical): Astellas Pharma has historically pursued life cycle management strategies for its drugs. However, with generic entry, significant new investments in life cycle management for branded MYRBETRIQ are less likely.
What is the Future Outlook for MYRBETRIQ GRANULES?
The future outlook for branded MYRBETRIQ GRANULES is characterized by continued decline in revenue and market share as generic mirabegron solidifies its position.
- Dominance of Generics: The mirabegron molecule will likely remain a significant treatment option for OAB, but predominantly in its generic forms. Generic mirabegron is expected to capture the vast majority of the market share.
- Niche Market for Branded Product: A small residual market for branded MYRBETRIQ may persist among patients with specific insurance plans that favor branded drugs, or in institutions that have existing contracts or stocking preferences. However, this segment will continue to shrink.
- Astellas Pharma's Strategy: Astellas Pharma will likely focus its resources on other pipeline assets and commercialized products, rather than significant investment in promoting branded MYRBETRIQ. The company's revenue will increasingly come from its generic mirabegron business or other therapeutic areas.
- Impact on Healthcare Costs: The widespread availability of generic mirabegron is expected to contribute to cost savings within the healthcare system for OAB treatment, aligning with payer objectives.
Key Takeaways
- MYRBETRIQ GRANULES (mirabegron extended-release) is a prescription medication for overactive bladder.
- The drug's market trajectory is heavily influenced by its patent expiration dates. Key patents protecting mirabegron have expired or are nearing expiration in major markets.
- Generic mirabegron products have entered the market, leading to significant price erosion and a decline in revenue for branded MYRBETRIQ.
- The OAB market is competitive, with anticholinergic agents (both branded and generic) representing major therapeutic alternatives.
- While branded MYRBETRIQ's revenue is declining, the mirabegron molecule will likely remain a relevant OAB treatment option through its generic forms.
Frequently Asked Questions
-
When did MYRBETRIQ GRANULES first receive FDA approval?
MYRBETRIQ GRANULES received U.S. Food and Drug Administration (FDA) approval in June 2012. [1]
-
What is the primary therapeutic difference between MYRBETRIQ and traditional anticholinergic OAB medications?
MYRBETRIQ is a beta-3 adrenergic agonist that relaxes the bladder detrusor muscle, increasing bladder capacity. Traditional anticholinergic OAB medications work by blocking acetylcholine, which also reduces bladder muscle contractions. [2]
-
What impact has the introduction of generic mirabegron had on Astellas Pharma's sales of MYRBETRIQ?
The introduction of generic mirabegron has led to a significant decline in sales revenue for branded MYRBETRIQ, as is typical following patent expirations and generic market entry.
-
Are there any other approved indications for MYRBETRIQ GRANULES beyond overactive bladder?
As of the last major patent expiries, MYRBETRIQ GRANULES is approved for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urge urinary frequency. There are no other major approved indications for this specific formulation.
-
What is the typical patient profile for whom MYRBETRIQ GRANULES was initially prescribed over other OAB treatments?
MYRBETRIQ GRANULES was often prescribed for patients who experienced intolerable side effects with anticholinergic medications, such as dry mouth, constipation, or cognitive impairment, or for those who did not achieve adequate symptom control with anticholinergics. [3]
Citations
[1] U.S. Food & Drug Administration. (2012, June 28). FDA approves MYRBETRIQ™ (mirabegron) tablets, the first and only FDA-approved beta-3 adrenergic agonist for the treatment of overactive bladder (OAB). U.S. Food & Drug Administration. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-approves-myrbetriq-mirabegron-tablets-first-and-only-fda-approved-beta-3-adrenergic-agonist-treatment
[2] Nitti, V. W. (2014). Mirabegron: a novel beta-3 agonist for the treatment of overactive bladder. Korean Journal of Urology, 55(3), 165–173. doi:10.4111/kju.2014.55.3.165
[3] Chapple, C. R., & Wein, A. J. (2011). Mirabegron: a new gold standard for the treatment of overactive bladder?. International Journal of Clinical Practice, 65(9), 904–907. doi:10.1111/j.1742-1241.2011.02743.x
